United States mRNA Vaccine and Therapeutics Market (2025-2033) | mRNA Vaccines, RNA Vaccines, COVID Legacy, Therapeutics Pipeline, Next-Gen Vaccines, RNA Drugs, Regulatory Approvals & Global Drug Development Ecosystem

mRNA Vaccines and Therapeutics market size reached US$ 46.32 Billion in 2024 and is expected to reach US$ 200.11 Billion by 2033, growing at a CAGR of 18.4% during the forecast period 2025-2033.

the prophylactic vaccines segment emerged as one of the fastest-growing categories, valued at US$ 32.97 billion In 2022, and further expanded to US$ 34.28 billion in 2023.

North America held the leading position in the global mRNA vaccines and therapeutics market in 2022, with a market size of US$ 18.22 billion, which grew to US$ 18.96 billion in 2023.

Asia-Pacific demonstrated robust growth, rising from US$ 7.53 billion in 2022 to US$ 7.91 billion in 2023, supported by increasing investments and expanding demand across emerging economies such as China and India.

Connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/mrna-vaccine-and-therapeutics-market?kb

United States: Recent Industry Developments
✅ March 2026: Moderna Inc. advanced late-stage clinical development of personalized mRNA cancer vaccine candidates, expanding trial sites across multiple oncology indications including melanoma and lung cancer.

✅ February 2026: Pfizer Inc. and BioNTech SE scaled up U.S. manufacturing capacity for next-generation mRNA combination vaccines targeting influenza and COVID-19 to strengthen seasonal immunization programs.

✅ January 2026: Arcturus Therapeutics expanded its self-amplifying mRNA (saRNA) platform programs, focusing on respiratory vaccines and rare infectious disease prevention with enhanced dose efficiency.

✅ December 2025: CureVac N.V. strengthened its U.S. operational footprint through partnerships aimed at accelerating mRNA-based therapeutic development for oncology and infectious disease applications.

Download Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/mrna-vaccine-and-therapeutics-market?kb

List of Key Players 2026:

Azra Al, CureMetrix, Inc., ConcertAI, Immunai, MVision AI Inc., Paige AI, Inc., Mindpeak GmbH, Imagene AI Ltd., Predictive Oncology, and Tempus

Key Strategic Growth Forecast Projections 2026:

The Global mRNA Vaccine and Therapeutics Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.

Key Strategic Developments 2025-2026:

✅ May 2026: BioNTech expanded its late-stage oncology pipeline with multiple clinical readouts and continued advancement of mRNA-based cancer immunotherapies, supported by collaborations with partners including Bristol Myers Squibb and Genentech.

✅ April 2026: CureVac integration progress under BioNTech ownership strengthened mRNA design, delivery, and manufacturing capabilities, reinforcing Europe's position in next-generation mRNA therapeutics development.

✅ March 2026: Moderna advanced its strategy to expand beyond respiratory vaccines into oncology and rare disease applications, with multiple late-stage pipeline catalysts expected across its mRNA therapeutics portfolio.

✅ February 2026: BioNTech initiated legal and competitive positioning efforts around next-generation mRNA vaccine technologies while continuing development of improved-dose and variant-adapted vaccine platforms.

✅ January 2026: Moderna highlighted pipeline expansion in seasonal vaccines and oncology programs, supported by operational cost optimization and strengthening of its commercial mRNA franchise.

✅ December 2025: BioNTech maintained strong financial reserves and advanced its oncology-focused mRNA pipeline, while reducing dependence on COVID-19 vaccine revenues and increasing investment in therapeutic programs.

✅ November 2025: CureVac reported continued development progress in mRNA-based oncology candidates and strengthened strategic alignment following its integration trajectory with BioNTech.

How Our Market Research Process Works:

The global mRNA Vaccine and Therapeutics Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of mRNA Vaccine and Therapeutics adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.

Funding/M&A/partnerships 2025-2026:

• Apr 2026 - Gilead → Arcellx ($7.8B): acquisition strengthening Gilead's oncology cell therapy pipeline, particularly in next-generation CAR-T and hematologic cancer programs

• Apr 2026 - Gilead → Tubulis (up to $5B): ADC-focused acquisition to expand antibody-drug conjugate oncology platform capabilities

• Apr 2026 - Eli Lilly → CrossBridge Bio ($300M): acquisition to advance next-gen dual-payload antibody-drug conjugate oncology therapies

• Mar 2026 - Biogen → Apellis Pharmaceuticals ($5.6B): major acquisition adding complement pathway and ophthalmology/immunology assets including approved therapies like SYFOVRE

• Jan 2026 - GSK → RAPT Therapeutics ($2.2B): GSK agreed to acquire RAPT Therapeutics to strengthen its immunology and inflammatory disease pipeline, including access to late-stage allergy and immune-modulating assets

• Jan 2026 - Bristol Myers Squibb → Janux Therapeutics (up to $850M collaboration): strategic partnership to co-develop "masked" T-cell engager cancer immunotherapies with milestone-based payments

• Jan 2026 - Amgen → Dark Blue Therapeutics ($840M): acquisition of a UK biotech focused on small-molecule oncology and protein degrader programs, expanding Amgen's precision oncology portfolio

• Jan 2026 - Lilly → Repertoire Immune Medicines (up to $1.93B collaboration): immunology-focused partnership leveraging T-cell biology platforms for autoimmune disease therapies

Request Strategic Market Customization: https://datamintelligence.com/customize/mrna-vaccine-and-therapeutics-market?kb

Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company expanded collaboration programs to support mRNA vaccine distribution and localized manufacturing capabilities for advanced infectious disease prevention solutions in Japan.

✅ February 2026: Shionogi & Co., Ltd. progressed early-stage research initiatives in mRNA-based respiratory vaccines, focusing on next-generation influenza and pandemic preparedness platforms.

✅ January 2026: Daiichi Sankyo Company advanced its nucleic acid-based therapeutic pipeline, strengthening R&D efforts in mRNA vaccine delivery systems for oncology applications.

✅ December 2025: AnGes Inc. initiated new research collaborations to enhance mRNA and nucleic acid vaccine technologies aimed at improving stability and immune response efficiency.

Major Segments Opportunity 2026:

By Product Type: Prophylactic Vaccines, Therapeutic Vaccines, Therapeutic Drugs

By Application: Cancer, Infectious Diseases, Rare Genetic Diseases, Others

By End-user: Hospitals & Clinics, Research Organizations, Academic Institutes, Others

Regional Growth Intelligence for Market:

⇥ North America - Leads the mRNA vaccine and therapeutics market due to strong biotechnology infrastructure, advanced clinical research ecosystem, and high adoption of innovative vaccine platforms.
⇥ Europe - Strong presence driven by government-funded research programs, established pharmaceutical companies, and expanding applications in infectious diseases and oncology.

⇥ Asia-Pacific - Rapid growth supported by increasing investments in biotechnology, expanding vaccine manufacturing capabilities, and rising focus on advanced therapeutics development.

⇥ Latin America - Emerging adoption supported by improving healthcare systems, vaccine accessibility programs, and growing participation in global clinical trials.

⇥ Middle East & Africa - Developing market with gradual uptake driven by healthcare modernization initiatives and increasing focus on immunization and infectious disease control programs.

Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=mrna-vaccine-and-therapeutics-market?kb

Market Drivers 2026:

Expansion of preventive and therapeutic applications for mRNA platforms across infectious diseases, oncology, and rare genetic disorders is supporting broader clinical utilization.

Advancements in lipid nanoparticle (LNP) delivery systems are improving stability, cellular uptake, and in vivo expression efficiency of mRNA-based formulations.

Growing focus on rapid vaccine design and scalable production frameworks is enabling faster response to emerging viral outbreaks and pandemic preparedness programs.

Increasing investment from biotechnology firms and public health organizations is strengthening clinical pipelines for next-generation mRNA candidates.

Progress in personalized cancer immunotherapy is encouraging development of patient-specific mRNA vaccines targeting tumor-associated antigens and neoantigens.

Improvements in cold chain logistics and thermostable formulation research are enhancing distribution feasibility across diverse healthcare settings.

Expanding applications in protein replacement therapies and in vivo gene expression platforms are broadening the therapeutic scope of mRNA technology.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.